<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698618</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-15-10793</org_study_id>
    <secondary_id>2015-003621-33</secondary_id>
    <nct_id>NCT02698618</nct_id>
  </id_info>
  <brief_title>PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Investigacion Interhospitalaria Cardiovascular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Investigacion Interhospitalaria Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Ticagrelor has a protective effect on&#xD;
      microcirculation during percutaneous coronary interventions in patients with Diabetes&#xD;
      mellitus type II or in a pre-diabetic status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Patients with Diabetes Mellitus (DM) Type 2 still consistently perform worse than their&#xD;
      non-diabetic counterparts especially in the setting of Percutaneous Coronary Intervention&#xD;
      (PCI). The abnormal coronary microcirculation along with the higher risk of distal&#xD;
      embolization of particles released from the PCI target lesion constitutes the main cause of&#xD;
      peri-procedural microcirculatory damage.&#xD;
&#xD;
      New antiplatelet agents, in particular Ticagrelor, might also play a protective role on&#xD;
      microcirculation. Ticagrelor inhibits cellular uptake of adenosine, increasing the&#xD;
      circulating levels of adenosine through the inhibition of its physiological clearance.&#xD;
      Adenosine may protect the myocardium from both ischemic, and reperfusion injury via its&#xD;
      potent vasodilatory effects and possibly by anti-inflammatory and antiplatelet properties.&#xD;
&#xD;
      Additionally previous research have identified a more profound effect of adenosine on&#xD;
      microcirculatory resistance associated to obesity and diabetes and a higher myocardial&#xD;
      protective effect of Ticagrelor during PCI might be expected in this high risk subgroup of&#xD;
      patients.&#xD;
&#xD;
      The purpose of PRotective Effect on the Coronary Microcirculation of Patients With DIabetes&#xD;
      by Clopidogrel or Ticagrelor (PREDICT) trial was designed to investigate the protective&#xD;
      effect of Ticagrelor on microcirculation during PCI in stable diabetic patient&#xD;
&#xD;
      Rationale:&#xD;
&#xD;
        1. Coronary plaques at high risk for distal embolization during PCI, like the one with&#xD;
           thin-cap fibroatheroma (TCFA), are more prevalent in patient with DM. Thus, this&#xD;
           population is at high risk to develop myocardial injury and microcirculation impairment&#xD;
           subsequent to PCI.&#xD;
&#xD;
        2. By blocking the Adenosine transporter (ENT) 1 nucleoside cell membrane transporter,&#xD;
           Ticagrelor inhibits cellular uptake of adenosine, increasing the circulating levels of&#xD;
           adenosine through the inhibition of its physiological clearance. Adenosine may protect&#xD;
           the myocardium from both ischemic, and reperfusion injury via its potent vasodilatory&#xD;
           effects and possibly by anti-inflammatory and antiplatelet properties. This translates&#xD;
           into an adenosine-mediated vasodilatory effect of ticagrelor that takes place soon after&#xD;
           loading dose.&#xD;
&#xD;
        3. Previous research from our group have identified a more profound effect of adenosine on&#xD;
           microcirculatory resistance associated to obesity and diabetes and a higher myocardial&#xD;
           protective effect of Ticagrelor during PCI might be expected in this high risk subgroup&#xD;
           of patients. (enhanced microcirculatory response to raised adenosine levels).&#xD;
&#xD;
      Giving these premises in diabetics or pre-diabetics patients, Ticagrelor treatment pre-PCI&#xD;
      might improve microcirculatory parameters (lower resistance) compared with clopidogrel&#xD;
      (secondary hypothesis). Ticagrelor might be superior to clopidogrel in providing&#xD;
      microcirculatory protection during PCI procedures in the same subgroup of patients (primary&#xD;
      hypothesis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta IMR post-PCI</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Absolute difference in the IMR value associated to PCI [&quot;Delta IMR Post-PCI&quot; = (IMR value post-PCI) minus (IMR value pre-PCI)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta IMR pre-PCI</measure>
    <time_frame>at least 48 hours after randomization, just before PCI and stenting.</time_frame>
    <description>Absolute difference in the IMR value associated to PCI [&quot;Delta IMR Pre-PCI&quot; = (IMR value pre-PCI) minus (IMR value at baseline)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial necrosis associated to PCI damage</measure>
    <time_frame>at least 72 hours, at the time of hospital discharge.</time_frame>
    <description>Myocardial necrosis associated to PCI damage, assessed by cardiac markers (troponin rise &gt; 5 times 99th percentile of upper reference limit or as elevation of CK-MB 3 times the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IMR post-PCI</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Absolute resistance value after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe microcirculatory impairment</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Incidence of severe microcirculatory impairment defined as Index of Microvascular Resistance &gt; 29 after PCI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Delta IMR post-PCI in subject with BMI = or &gt; 30</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Absolute difference in the IMR value associated to PCI [&quot;Delta IMR Post-PCI&quot; = (IMR value post-PCI) minus (IMR value pre-PCI)] in subject with BMI = or &gt; 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Delta IMR pre-PCI in subject with BMI = or &gt; 30</measure>
    <time_frame>at least 48 hours after randomization, just before PCI and stenting.</time_frame>
    <description>Absolute difference in the IMR value associated to PCI [&quot;Delta IMR Post-PCI&quot; = (IMR value post-PCI) minus (IMR value pre-PCI)] in subject with BMI = or &gt; 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial necrosis associated to PCI damage in subject with BMI = or &gt; 30</measure>
    <time_frame>at least 72 hours, at the time of hospital discharge.</time_frame>
    <description>Myocardial necrosis associated to PCI damage, assessed by cardiac markers (troponin rise &gt; 5 times 99th percentile of upper reference limit or as elevation of CK-MB 3 times the upper limit of normal in subject with BMI = or &gt; 30</description>
  </other_outcome>
  <other_outcome>
    <measure>IMR post-PCI in subject with BMI = or &gt; 30</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Absolute resistance value after PCI in subject with BMI = or &gt; 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe microcirculatory impairment in subject with BMI = or &gt; 30</measure>
    <time_frame>at least 48 hours after randomization, just after PCI and stenting.</time_frame>
    <description>Incidence of severe microcirculatory impairment defined as Index of Microvascular Resistance &gt; 29 after PCI in subject with BMI = or &gt; 30</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic</intervention_name>
    <description>Pre-PCI and treatment:&#xD;
At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.&#xD;
At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Randomization</intervention_name>
    <description>Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated&#xD;
PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.&#xD;
Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR).</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with Diabetes Mellitus (DM) Type II&#xD;
&#xD;
          -  Subject must be older than 18 years&#xD;
&#xD;
          -  Written informed consent available&#xD;
&#xD;
          -  Subject with stable ischemic heart disease referred for coronary angiography&#xD;
&#xD;
          -  Subject is eligible for PCI, and PCI target(s) have FFR≤0.80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior myocardial infarction in the territory of the target vessel&#xD;
&#xD;
          -  Akinesia or dyskinesia in subtended myocardial segments&#xD;
&#xD;
          -  Severe impairment of left ventricular function (LVEF) &lt;35%&#xD;
&#xD;
          -  PCI target is a chronic total occlusion&#xD;
&#xD;
          -  Target lesion has been treated previously (restenotic lesions)&#xD;
&#xD;
          -  Target vessel is a saphenous vein graft or a surgical graft has been anastomosed to&#xD;
             target vessel&#xD;
&#xD;
          -  Thrombolisis in Myocardial Infarction (TIMI) flow ≤ 1 prior to guide wire crossing&#xD;
&#xD;
          -  Subject is not eligible for treatment with DES&#xD;
&#xD;
          -  Bleeding disorders or chronic anticoagulant treatment&#xD;
&#xD;
          -  Left main stenosis &gt; 50%&#xD;
&#xD;
          -  Coronary surgery deemed more beneficial for the patient than PCI&#xD;
&#xD;
          -  Intolerance or contraindications to anti-platelet drugs&#xD;
&#xD;
          -  Contraindications for adenosine administration&#xD;
&#xD;
          -  Platelet count &lt;75000 or &gt;700000/mm3&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Pregnant or breast feeding patient&#xD;
&#xD;
          -  History of intracranial haemorrhage&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Escaned, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Cerrato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Luigi Gonzaga University Hospital, Orbassano (Turin), Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Escaned, MD, PhD</last_name>
    <phone>+34913303438</phone>
    <email>javier.escaned@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Cerrato, MD</last_name>
    <email>enrico.cerrato@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José M de la Torre, MD, PhD</last_name>
      <phone>+34 942202520</phone>
    </contact>
    <investigator>
      <last_name>José M de la Torre, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José R Rumoroso, MD, PhD</last_name>
      <phone>+34 944007000</phone>
    </contact>
    <investigator>
      <last_name>José R Rumoroso, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Escaned, MD, PhD</last_name>
      <phone>+34913303438</phone>
      <email>javier.escaned@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Enrico Cerrato, MD</last_name>
      <email>enrico.cerrato@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Escaned, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Quirós, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>February 27, 2016</last_update_submitted>
  <last_update_submitted_qc>February 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Javier Escaned</investigator_full_name>
    <investigator_title>Unit head</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>IMR</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>CFR</keyword>
  <keyword>FFR</keyword>
  <keyword>Coronary microcirculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

